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Abstract: Cone snails produce a fast-acting and often paralyzing venom, largely dominated by
disulfide-rich conotoxins targeting ion channels. Although disulfide-poor conopeptides are usually
minor components of cone snail venoms, their ability to target key membrane receptors such as
GPCRs make them highly valuable as drug lead compounds. From the venom gland transcriptome
of Conus miliaris, we report here on the discovery and characterization of two conopressins, which are
nonapeptide ligands of the vasopressin/oxytocin receptor family. These novel sequence variants show
unusual features, including a charge inversion at the critical position 8, with an aspartate instead
of a highly conserved lysine or arginine residue. Both the amidated and acid C-terminal analogues
were synthesized, followed by pharmacological characterization on human and zebrafish receptors
and structural investigation by NMR. Whereas conopressin-M1 showed weak and only partial
agonist activity at hV1bR (amidated form only) and ZFV1a1R (both amidated and acid form), both
conopressin-M2 analogues acted as full agonists at the ZFV2 receptor with low micromolar affinity.
Together with the NMR structures of amidated conopressins-M1, -M2 and -G, this study provides
novel structure-activity relationship information that may help in the design of more selective ligands.
Keywords: conopressin; vasopressin; venom; cone snail; conotoxin
1. Introduction
Cone snail venoms represent a unique source of hundreds of thousands of bioactive peptides, yet it
is estimated that less than 1% of this diversity has been pharmacologically characterized. Nevertheless,
the therapeutic potential of Conus venom is undeniable, with one peptide approved by the FDA for
the treatment of chronic pain [1–3], and several others that are in clinical trials. Furthermore, these
natural peptides have become indispensable tools to decipher the physiological role and function of
various ion channel subtypes and other membrane receptors [4,5]. Conus peptides are divided into
two mains groups, based on the number of disulfide bonds; the disulfide-poor conopeptides (0 or
1 disulfide bond) and the disulfide-rich conotoxins (two or more disulfide bonds) [6]. Disulfide-poor
conopeptides are usually minor components of cone snail venom, but interestingly several subclasses,
such as the contulakins or ρ-conopeptides, target G protein-coupled receptors (GPCRs) [6]. Although
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less abundant than the conotoxins that target ion channels, recent venomics analyses of venom glands
have revealed these disulfide-poor conopeptides remain an untapped resource of novel bioactives.
The first vasopressin-oxytocin-related conopeptides, Lys-conopressin-G and Arg-conopressin-S,
were isolated more than thirty years ago from the venom of two piscivorous species, Conus geographus
and Conus striatus, respectively [7]. Intracerebral injection into mice induced similar effects compared
to neurohypophysal hormone injection, and therefore, it was hypothesized that conopressin-G/S might
act as agonists of the same class of GPCR in the brain. While only one subtype of OTR (oxytocin
receptor) has been identified, three different vasopressin receptor subtypes have been characterized
that possess different pharmacological and G protein-coupling properties [8]. V2 receptors (V2Rs) are
coupled to adenylyl cyclase and their activation produces an antidiuretic effect via the kidneys. V1aR
and V1bR, as well as OTR are coupled to phospholipase C but produce different biological effects upon
activation: the V1aR regulates blood pressure and vasoconstriction, whereas the V1bR is responsible for
the corticotrophin release from the pituitary gland. Compounds targeting the OTR are used clinically
to stimulate the contraction of uterine and mammary myocytes [9,10]. Interestingly, unlike vasopressin
and oxytocin, conopressin-G and -S display an additional positive charge at position 4, which is only
found in two other endogenous vasopressin analogues, namely cephalotocin (Octopus vulgaris) and
annetocin (Eisenia foetida) [7,11]. Lys-conopressin-G was later isolated from other non-venomous snail
species and was therefore proposed as an endogenous invertebrate vasopressin analog. Consequently,
an underlying question is to determine whether conopressins are simply endogenous or true venom
peptides in cone snails, since a role in prey capture has never been demonstrated. However, given
that more conopressin variants have been identified in different venomous cone snail species, it
clearly suggests they are venom peptides with the typical diversification observed in conotoxins [12].
Among them is the unique γ-conopressin-vil purified from Conus villepinii venom, which displays
a carboxyglutamate residue conferring the capacity of the peptide to change its conformation in
the presence of calcium ions [13]. Another unique example is conopressin-T isolated from Conus tulipa,
which, unlike vasopressin-oxytocin related peptides, is a selective antagonist of V1a receptors [11].
Interestingly, position 9 was described as an antagonist switch and replacement of glycine at this
position by a valine residue turns oxytocin and Arg-Vasopressin (AVP) from full agonists to full
antagonists. The L7P-conopressin-T mutant displays an increased affinity for the V1a receptors,
whereas activity at the V1b and V2 receptors remains unchanged, suggesting a favorable V1aR selective
conformational change induced by the proline residue [11].
Docking studies on a three-dimensional model of the V1a receptor revealed that Arg-vasopressin
binds into a 15-20 Å deep cleft defined by the transmembrane helices of the receptor. Residues located
in this region that interact with agonist ligands are highly conserved in all the vasopressin and oxytocin
receptors suggesting the agonist-binding pocket is common to all the different subtypes of this receptor
family [11]. Interestingly, mutations of residues located in the receptor agonist binding site do not
affect antagonist activity, suggesting a different binding mode for antagonist ligands [11]. Indeed,
the different binding sites of various antagonist ligands are formed by transmembrane helices 1, 2 and
7, whereas the agonist binding site is mainly made by the three extracellular domains of the oxytocin
receptor, as evidenced by Postina et al. [14]. Based on the bovine rhodopsin structure, three-dimensional
molecular models of the V1aR and V1bR complexed with vasopressin suggested that four key residues
fine tune the binding of vasopressin and related peptide agonists to both receptor subtypes [15]. While
these predictions have been validated by receptor mutants and may enable the design of V1a and V1b
receptor selective agonists, more information on structure-activity relationships of novel ligands are
highly desirable [15].
In this study, we report on the synthesis, pharmacological characterization and structure of
two new conopressin-related peptides identified in Conus miliaris transcriptome. All peptides were
characterized on both human and zebrafish receptors using conopressin-G, vasotocin, oxytocin and
vasopressin as controls. Together with their NMR structures and considering their unique sequences,
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this study provides valuable structure-function information that might be useful to guide the design of
new vasopressin receptor selective ligands.
2. Results
Two new conopressin-related sequences were identified in the venom gland transcriptome of
the vermivorous species Conus miliaris. Both sequences had the characteristic mature nonapeptide
containing one disulfide bond forming a six-membered ring plus three exocyclic residues. Most
surprisingly, both sequences displayed very unusual substitutions, including an aspartic acid instead
of the highly conserved basic residue at position 8, a serine instead of the highly conserved amidated
glycine at the C-terminal (C-ter), and conopressin-M1 has also a proline residue in position 3 (Figure 1A).
Considering the positions of these unusual substitutions, including in the functionally critical exocyclic
region, it was of interest to investigate the pharmacological and structural properties of these
novel conopressins.
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by a  serine  residue  in conopressin‐M1 and M2.  (B) RP‐HPLC/ESI‐MS analyses of  the  synthesized 
conopressins. Acetonitrile (ACN) gradient from 0% to 30% over 30 min. For Con‐M1 the two peaks 
display the same mass, possibly caused by the two proline residues inducing cis‐trans isomerization 
causing dynamic conformational exchange leading to the splitting of the UV chromatogram peak [16–
18]. The asterisk (*) on ESI‐MS insets indicate an ion resulting from in source fragmentation of the 
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peptides. Con‐G  from the piscivorous C. geographus was also synthesized as  its three‐dimensional 
structure is unknown and its pharmacological characterization mostly incomplete. After RP‐HPLC 
purification of  the  folded peptide,  the homogeneity was assessed by analytical RP‐HPLC and MS 
(Figure 1B). Pure peptide yields were nearly two‐fold better for the amidated peptides (around 30% 
compared to acid peptides around 17%), which can be attributed to the better stability of the amide 
versus the ester bond to the linker. The Con‐G yield was up to 70%, however, and it is difficult to 
Figure 1. RP-HPLC/ESI-MS analyses of the synthesized conopressins and alignment of
conopressin-related sequences. (A) Alignment of conopressin-related sequences. The asterisks
* indicate an amidated C-terminal. Conopressin-M1 and M2 with γ-conopressin-vil are the only
sequences that display a negatively charged amino acid at position 8. Interestingly, conopressin-M1
also displays an unusual proline residue at position 3. The highly conserved glycine residue at
position 9 is replaced by a serine residue in conopressin-M1 and M2. (B) RP-HPLC/ESI-MS analyses
of the synthesized conopressins. Acetonitrile (ACN) gradient from 0% to 30% over 30 min. For
Con-M1 the two peaks display the same mass, possibly caused by the two proline residues inducing
cis-trans isomerization causing dynamic conformational exchange leading to the splitting of the UV
chromatogram peak [16–18]. The asterisk (*) on ESI-MS insets indicate an ion resulting from in source
fragmentation of the proline residue [19].
2.1. Chemical Synthesis
All conopressins discovered to date have an amidated C-terminal, yet the precursors of
the conopressin-M1/M2 sequences do not display the usual G10K11R12 motif (data not hown),
which is a typical enzymatic recognition ite where the glycine residue at positi n 10 is enzymatically
converted to a C-terminal amide group [20]. Therefore, without MS evidenc for one or the ther, we
synthesized both C-terminal amide (Con-M1/M2am) and acid (Con-M1/M2ac) versions of the p ptides.
Con-G from the piscivorous C. geographus was also synthesized as its three-dimensional structure is
unknown and its pharmacological characterization mostly inc mplete. After RP-HPLC purification of
the fold d peptide, the homogeneity was assessed by analytical RP-HPLC and MS (Figure 1B). ure
eptide yields were nearly two-fold b tter f r the amid ted p pti es (around 30% compared to acid
peptides around 17%), which can b attributed to the better stability of the amide versus the ester
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bond to the linker. The Con-G yield was up to 70%, however, and it is difficult to conclude if this
difference arises from a better folding yield or a better synthesis yield, since linear products have not
been isolated and purified prior to oxidation given the size of the peptides.
2.2. NMR Spectroscopy
One-dimensional and two-dimensional NMR spectra were recorded on the conopressin peptides
to provide insight into the solution structures. The spectra of Con-M1 contain additional peaks,
indicative of multiple conformations. By contrast, Con-G and Con-M2 display predominately one
set of peaks, indicating that divergent conformations are not present in solution for these peptides.
Despite the presence of multiple conformations for the Con-M1 peptides, the major conformation could
be assigned. Comparison of the chemical shifts between the amide and acid forms of Con-M1 and
Con-M2 shows that the state of the C-terminal residue does not impact the structure as the chemical
shifts are very similar between the two peptides as shown in Figure 2.
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Figure 2. Three‐dimensional structures of Con‐G, Con‐M1, Con‐M2 and Con‐T. The 20 lowest NMR 
structures are superimposed over the backbone atoms. The backbone is shown in ribbon format and 
the side‐chains as sticks. Proline  residues bringing constraints  to  the structures are highlighted  in 
yellow. 
Figure 2. Three-di ensional structures of Con-G, Con- 1, Con- 2 and Con-T. The 20 lowest NMR
structures are superimposed over the backbone atoms. The backbone is shown in ribbon format
and the side-chains as sticks. Proline residues bringing constraints to the structures are highlighted
in yellow.
Given the similarity between the acid and amide forms of the peptides, the three-dimensional
structures of only the amide forms of Con-M1 and Con-M2 were calculated. The three-dimensional
structure of Con-G (containing a C-terminal amide) was also determined. Despite the small size of
these peptides, relatively well-defined structures could be determined, with calculated RMSD for
the 20 best structures (values for backbone residues) of 0.895, 0.676 and 1.664 Å for Con-G, Con-M1
and Con-M2 respectively. The lower RMSD value of Con-M1 could be attributed to the proline residue
in position 3 which seems to further constrain the backbone (Figure 2). Overall, the structures appear
slightly different to the previously described Con-T [11], where the three exocyclic residues are more
flexible (Figure 2) due to the absence of the conserved and structurally constrained proline residue in
position 7. The structures of the three peptides are similar and they do not contain regular secondary
structure but rather a turn region formed by the disulfide bond between Cys1 and Cys6. Deuterium
exchange experiments can provide insight into residues likely to be involved in hydrogen bonds. 1D
and TOCSY spectra were recorded following dissolution of the peptides in 100% D2O and based on
these experiments Con-M1 and Con-M2 display slowly exchanging amide protons (at least 4-6 residues).
The majority of peaks are exchanged within 30 minutes but the detection of amide protons in the D2O
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solution, particularly for such small peptides, suggests that the amide protons are protected from
the solvent to some extent and are likely to be involved in hydrogen bonds that stabilize the structures.
By contrast, the amide peaks of Con-G are exchanged within 10 minutes and could not be identified
using TOCSY spectra.
2.3. Pharmacological Characterization on Human and Zebrafish Receptors
We performed a fluorescent imaging plate reader (FLIPR) Ca2+ mobilization assay and
a second-messenger cyclic adenosine monophosphate (cAMP) assay (for V2R) to determine
the biological activity of the four new conopressins and Con-G. Considering this structure-activity
relationship (SAR) study from a drug design perspective, we investigated the agonist and antagonist
activity of the conopressins on the human oxytocin receptor (hOTR), human vasopressin-1a receptor
(hV1aR), human vasopressin-1b receptor (hV1bR) and human vasopressin2 receptor (hV2R). However,
since Conus geographus is a piscivorous cone snail feeding on fish, it was of interest to also investigate
conopressin activities on zebrafish (Danio rerio) receptors, namely zebrafish vasopressin1-a1 receptor
(ZF V1a1R), zebrafish vasopressin1-a2 receptor (ZF V1a2R), zebrafish vasopressin2 receptor (ZF V2R)
and zebrafish oxytocin/isotocin receptor (ZF oxy/isoR) (Figures 3 and 4). Oxytocin, vasopressin and
vasotocin were used as reference compounds.
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Figure 3. Representative concentration-response curves measuring increasing concentrations of
intracellular calcium using a FLIPR assay for the hOTR, hV1aR and hV1bR, and representative
concentration-response curves measuring accumulation of cAMP using a cAMP signaling assay for
the hV2R of all tested compounds. Each point represents the mean of measurements from one
experiment performed in triplicate. Error bars represent S.E.M.
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Overall, we can delineate roughly three classes of potency: (i) reference compounds displaying
EC50 values in the picomolar/nanomolar range, (ii) Con-G exhibiting potencies in the high nanomolar
range and iii) C. miliaris conopressins that mostly show no or weak activity, except at the ZF V2R
with an EC50 in the micromolar range. The micromolar range affinity displayed by the C. miliaris
conopressin peptides clearly emphasize the negative influence of the conserved residue substitutions,
which will be further discussed. Interestingly, we demonstrate for the first time that Con-G is more
active on fish receptors than on their human counterparts, which supports an evolved role of Con-G in
the envenomation process, although more direct evidence is required. Con-G acts as a partial agonist
at hOTR, ZF V1a2R and ZF oxy/isoR with 28%, 69% and 62% response of control respectively, but
as a full agonist at all other receptors. Con-M1am is the only C. miliaris peptide showing a weak
and partial agonist response at hV1b and hV1a with 26% and 58% response of control, respectively.
Somehow expectedly, endogenous mammalian peptides (oxytocin and vasopressin) are more active
than the non-mammalian vasotocin peptide at all human receptors except for the OTR. Inversely,
vasotocin (fish endogenous ligand) was more active than mammalian peptides at all zebrafish receptors,
which is consistent from an evolutionary point of view. The EC50 values are reported in Table 1. There
was no antagonist activity detected for any of the synthesized conopressins up to 10 µM and control
compounds did not induce a response in untransfected cells, which confirms that our responses are
receptor specific (data not shown).
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Table 1. Mean EC50 (nM) values of all tested peptides on all receptors (min. three independent experiments). Amino acid substitutions relative to vasotocin inducing
pharmacological properties differences are highlighted. Arrows indicate lower (down) or higher (up) EC50 for the tested peptides relative to vasotocin mean EC50
values. Selectivity values are calculated according to the highest EC50 value. Boxes indicate significant changes relative to vasotocin. Standard errors of the mean are
indicated in brackets. N.D means not determined because of high value > 100 µM.
Name Sequence hOTR hV1aR hV1bR hV2R ZF V1a1R ZF V1a2R ZF V2R ZF oxy/isoR Selectivity
Vasotocin CY I Q NCP R G*
1.62
(±0.51)
15.92
(±4.57)
4.26
(±1.11)
0.00055
(±0.0003)
0.41
(±0.11)
2.77
(±3.33)
5.07
(±1.19)
0.85
(±0.14)
hV2R (x28945.5) > ZF V1a1R (x38.8)
> ZF oxy (x18.7) > hOTR(x9.8) > ZF
V1a2R (x5.7) > hV1bR (x3.7) > ZF
V2R (x3.1) > hV1aR
Oxytocin CYIQNCP L G*
4.57↗
(±1.60)
89.26↗;
(±5.12)
84.92↗
(±6.44)
0.24 ↗
(±0.14)
3.68↗
(±1.70)
8.02↗
(±1.44)
15.98↗
(±1.64)
1.74↗
(±0.75)
hV2R (x371.9) > ZF oxy (x51.3) >
ZF V1a1R (x24.3) > hOTR(x19.5) >
ZF V1a2R (x11.1) > ZF V2R (x5.6) >
hV1bR (x1.1) > hV1aR
Vasopressin CY F QNCPRG*
8.86↗
(±2.85)
3.33 ↘
(±0.81)
1.30 ↘
(±0.27)
0.00058=
(±0.0004)
1.28↗
(±0.19)
8.24↗
(±0.28)
4.97=
(±0.80)
7.42↗
(±0.08)
hV2R (x15275.9) > ZF V1a1R =
hV1bR (6.9) > hV1aR (x2.7) > ZF
V2R (x1.8) > ZF oxy (x1.2) > ZF
V1a2R (x1.1) > hOTR
Con-G CFI R NCPKG* 455.66 ↗
(±39.27)
123.78↗
(±27.35)
51.92↗
(±8.37)
299.2 ↗
(±11.32)
10.61↗
(±1.87)
44.06↗
(±7.42)
61.05↗
(±12.80)
353.73 ↗
(±12.43)
ZF V1a1R (x42.9) > ZF V1a2R (x10.3)
> hV1bR (x8.8) > ZF V2R (x7.5) >
hV1aR (x3.7) > hV2R (x1.5) >
ZF oxy (x1.3) > hOTR
Con-M1ac CFPGNCPDS N.D N.D N.D N.D 116 950 N.D N.D N.D
Con-M1am CFPGNCPDS* N.D N.D 38 194 N.D 13 614(±9807) N.D N.D N.D
Con-M2ac CFLGNCPDS N.D N.D N.D N.D N.D N.D 3656(±2173) N.D
Con-M2am CFLGNCPDS* N.D N.D N.D N.D N.D N.D 1722(±637) N.D
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3. Discussion
Conopressins are vasopressin-like peptides originally found in the venom of piscivorous cone
snails (Con-G from C. geographus and Con-S from C. striatus) [7]. Lys-conopressin G was later found in
the venom of the vermivorous C. imperialis as well as other non-venomous snails, suggesting that it may
represent an endogenous peptide [21]. However, more recent reports describing divergent sequences
of conopressins such as γ-conopressin-vil or Con-T support their role as venom peptides [11,13]. In this
study, we describe two novel vasopressin-like sequences retrieved from the venom gland transcriptome
of the vermivorous Conus miliaris, conopressin-M1 and -M2. Given the unusual sequence deviation of
these conopressins compared to currently known oxytocin/vasopressin related peptides, (i.e., proline
residue at position 3 of Con-M1, glycine at position 4, negatively charged aspartic acid at position 8 in
place of conserved basic residue, and the lack of terminal glycine residue (Figure 1A)), it was of interest
to investigate their structure and pharmacological profile. It has previously been demonstrated that
a glycine substitution by a valine residue at position 9 will switch oxytocin and AVP from agonist
to antagonist [11]. Using chemical synthesis, the C-terminal acid and amide of each of the novel
conopressin peptides (Con-M1ac/am, Con-M2ac/am) were obtained with good purity and in sufficient
yield to perform pharmacological and structural characterization. Since the pharmacological profile of
conopressin-G is still poorly characterized and its structure unknown, this peptide was also synthesized
for comparative purposes. Interestingly, Con-M1 did not resolve as a sharp UV peak but instead
two partially separated peaks displaying the same mass. Possibly, the additional proline residue
at position 3 of Con-M1 peptides may cause dynamic conformational exchanges between cis-trans
isomerization, a conformational heterogeneity that has been described in other conotoxins [16–18]. This
explanation is consistent with the NMR spectra of the Con-M1 peptides, which display the presence of
multiple conformations.
Pharmacological characterization of all peptides was carried out on human AVP and OT receptors
and for the first time also on zebrafish receptors. Besides AVP and OT, vasotocin (fish endogenous
ligand) was also tested as a reference. Not surprisingly, AVP and OT show higher affinity for human
receptors compared to vasotocin, whereas the opposite was true on fish receptors. The only exception
concerns a slightly more active vasotocin (1.62 nM) at human OTR compared to OT (4.57 nM) and AVP
(8.86 nM). Contrasting results were obtained regarding the activity of the conopressins. Con-G, which
possesses a basic residue in position 8, acts as a full agonist at all human receptors, except OTR. Con-G
was as potent as oxytocin on hV1aR and hV1bR, with EC50 in the high nM range (52-123 nM), yet it
displays lower affinity at the hV2R (300 nM). Higher affinities were achieved for Con-G at the zebrafish
receptors, particularly at the ZF V1a1R (EC50 = 10 nM). As anticipated from the absence of a basic
residue at position 8, C. miliaris conopressins showed no or weak activity at all human receptors.
Only the amidated form of Con-M1 acted as partial agonist at the hV1AR and hV1bR. However, both
the acid and amidated Con-M2 were full agonists at the ZF V2R, with affinities in the low µM range
(1.7–3.6 µM).
In terms of SAR information from this work, it seems evident that an aromatic residue at position
3 improves the peptide selectivity for hV1aR and hV1bR, mostly by decreasing the potency at all
other receptors, especially ZF oxy/isoR. Furthermore, the presence of a basic residue instead of highly
conserved glutamine residue at position 4 reduces the potency at all tested receptors, particularly at ZF
oxy/isoR and hOTR, but even more drastically at hV2R. In order to gain insights into the interaction of
the peptides ligands with the receptors, Rodrigo et al. [15] built three-dimensional molecular models of
the complexes between AVP and the two receptor subtypes V1a and V1b based on the X-ray structure
of bovine rhodopsin. Their predictions have been confirmed by directed mutagenesis studies and four
key residues were identified that finely tune the binding of vasopressin and related peptide agonists to
both receptor subtypes. Indeed, Glu1.35 and Asp2.65 residues are described as key anchoring residues
to Arg8, which is evidenced by higher EC50 values of oxytocin, and similarly, explains the lack of
activity of the C. miliaris conopressins that do not display a basic residue in position 8.
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Interestingly, vasopressin and vasotocin are nearly 10,000-fold more potent on hV2R than on
ZF V2R (0.5 nM vs 5 µM), where they display EC50 values similar to oxytocin (16 µM), suggesting
a crucial role of the basic residue in position 8 to enable a tight interaction with hV2R but not with
ZF V2R. An alignment of hV2R and ZF V2R sequences reveals that all acidic residues important
for ligand binding located in the loop between TMVI and TMVII of hV2R are not conserved in ZF
V2R (Figure 5). Rodrigo et al. also identified Val4.31 and Pro5.35 as a hydrophobic subsite specific of
V1bR according to its high affinity with d[Cha4]AVP [15,22]. The latter probably partly explains why
vasopressin, which has a hydrophobic Phe residue at position 3, displays a slightly better affinity
at hV1b compared to vasotocin (Table 1). A previous study from Mouillac et al. has shown that
hydrophobic regions of the peptide hormones are accommodated by a hydrophobic pocket lying deep
in the 7-TM (transmembrane) domain delineated between TMIII and TMVI of V1aR [9,15], confirming
the slightly better affinity at hV1a compared to vasotocin. A tight hydrogen bond network also
contributes to crucial interactions with V1aR and V1bR. Indeed, conserved Gln residues located at
the rim of the cavity form hydrogen bond (H-bond) with side chains of Gln4 and Asn5 of the peptide
hormones [15]. As a result, substitution of the vasotocin glutamine residue at position 4 by an arginine
residue in Con-G leads to a loss of potency at hV1aR and hV1bR. Moreover, SAR studies show that
a glycine carboxamide moiety is required for biological activity, enabling H-bonds between AVP/OT
and Gln214, Gln218 of V1aR [9,23] and providing another plausible explanation for the lack of activity
of C. miliaris conopressins, where the terminal glycine residue is replaced by a serine residue.Mar. Drugs 2019, 17, x FOR PEER REVIEW  10  of  15 
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D297 in hV2R with S275 in ZF V2R is bordered in black. Asterisks (*) indicate amino-acid residues that
have been suggested to participate and to be important in receptor–ligand interaction. Arrows indicate
the seven putative transmembrane domains (TM 1–7).
In conclusion, the low activity on all tested receptors of Con-M1 and Con-M2 can be explained
by (i) the substitution of Gln4 by a glycine residue, (ii) the absence of a basic residue in position 8,
and (iii) the missing glycine residue in position 9. Overall, C. miliaris conopressins mostly show no or
reduced activity on all receptor tested, except at the ZF V2R where EC50 values are in the micromolar
range. Yegan h et al. [24] showed that residues involved in the binding site are W293, W296, D297,
A300, an P301. Our results suggest that there is an interaction between residue in position 8 of
th ligand nd D297 of the hV2R sinc the activity decreases (compared to vasotocin) for all ligands
that do no display a positiv ly charged residue in position 8. Interestingly, in the ZF V2R sequenc ,
the equivalent of residue D297 is substituted by a s rine residue (Figure 5), significantly reduci g
the potential lectrostatic repulsion with the aspartic residue in position 8 of t e C. milia is conopressins,
hence the detected activity of C. miliaris conop essins on ZF V2R over hV2R. From more ev lutionary
considerations, it is interesting to note that Con-G is more active on zebrafish (Danio r rio) receptors than
on the hu an counterpart recept rs, which is consistent with he piscivorous behavior of C. geographus
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and suggests a role for Con-G in the envenomation process. Given that C. miliaris is a worm hunting
cone snail (preys on Polychaeta worms), the interspecies receptor molecular differences (worm/fish)
may also account for the seemingly weak activities at zebrafish/human receptors of conopressin-M1 and
-M2. Supporting this hypothesis, among the neurohormones identified in the genome of the Polychaeta
worm Capitella teleta is an endogenous conopressin-like sequence devoid of basic residue at position
8 [25]. Future investigations should include a phylogenetic screening of conopressins based on
the diet of the species it was isolated from to better reflect on the true biological activities of these
venom peptides.
4. Materials and Methods
4.1. Abbreviations
Acm, acetamidomethyl; ACN, acetonitrile; Boc, tert-butoxycarbonyle; DCM, Dichloromethane;
DIPEA, diisopropylethylamine; DMF, N,N’-dimethylformamide; DTP, 2,2’-Dithiopyridine;
ESI-MS, electrospray ionization mass spectrometry; Fmoc, fluorenylmethoxycarbonyl; HATU,
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate;
LC/MS, liquid chromatography/mass spectrometry; MeOH, methanol; nAChR, nicotinic acetylcholine
receptor; NMR, nuclear magnetic resonance; Pbf, pentamethyl-dihydrobenzofuran-5-sulfonyl;
RP-HPLC, reversed-phase high performance liquid chromatography; SPPS, solid phase
peptide synthesis; t-Bu, tert-butyl;TFA, trifluoroacetic acid; TIS, triisopropylsilane; Tris,
2-Amino-2-(hydroxymethyl)propane-1,3-diol;Trt, trityl; UV, ultra-violet.
4.2. Chemical Synthesis
DMF, DIEA, ACN, TIS, TFA, piperidine and all other reagents were obtained from Sigma-Aldrich
(Saint-Louis, MI, USA) or Merck (Darmstadt, Allemagne) and were used as supplied. Fmoc (L)
amino acid derivatives and HATU were purchased from Iris Biotech (Marktredwitz, Germany).
AmphiSpheres™ 20 HMP resin (0.6 mmol/g) and Amphispheres™ 40 RAM (0.4 mmol/g) were
purchased from Agilent Technologies (Les Ulis, France). The following side-chain protecting groups
were used: Asn(Trt), Cys(Trt), Ser(tBu), Asp(OtBu), Lys(Boc), Arg(Pbf). Peptides were manually
synthesized by using the Fmoc-based solid-phase peptide synthesis technique on a VWR (Radnor, PA,
USA) microplate shaker. All Fmoc amino acids and HATU were dissolved in DMF to reach 0.5 M. For
acid peptides the first residue was anchored on 20 HMP resin using the method described by Grandas et
al. [26]. The resin was washed with DMF, DCM, MeOH, and DMF. Fmoc deprotection was carried out
with piperidine in DMF (1/2 v/v) twice for 3 min. Subsequent amino acids were coupled onto 0.1 mmol
of resin twice for 10 min using an amino acid/HATU /DIPEA ratio of 5:5:10 relative to resin loading.
DMF was used for resin washing between deprotection and coupling steps. After chain assembly
was complete, the terminal Fmoc group was removed and the resin washed with DMF and DCM.
Side-chain deprotection and cleavage from the resin was carried out by adding 10 mL of TFA/TIS/H2O
(95/2.5/2.5 v/v/v) and stirring the mixture for 2.5 h at room temperature. After the resin was removed
by filtration and washed three times with dichloromethane. Dichloromethane and TFA were removed
under vacuum then cold diethyl ether was added to precipitate the peptide. The disulfide bridge was
formed between the free cysteine residues by dissolving the peptide at 0.2 mM in 50 mM Tris-HCl
buffer adjusted to pH 8 and adding dropwise 7 equivalents of DTP at 10 mM in MeOH. When reaction
was complete, the reaction mixture was acidified to pH 3 and loaded onto preparative RP-HPLC and
pure fractions were combined. The combined pure fractions were freeze-dried and their purity were
confirmed by LC/ESI-MS.
4.3. Mass Spectrometry
Solvents used for LC/MS were of HPLC grade.
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Intermediate products were characterized using a LC/MS system consisting of a Waters (Milford,
OH, USA) Alliance 2695 HPLC, coupled to a Waters Micromass ZQ spectrometer (electrospray
ionization mode, ESI+). All the analyses were carried out using a Chromolith (Fontenay sous Bois,
France) HighResolution RP-18e (4.6 x 25 mm, 15 nm–1.15 µm particle size, flow rate 3.0 mL/min)
column. A flow rate of 3 mL/min and a gradient of 0%–100% B over 2.5 min for routine analyses and
0%–30% B over 30 min for quality control of pure products were used. Eluent A: water/0.1% HCO2H;
eluent B: acetonitrile/0.1% HCO2H. UV detection was performed at 214 nm. Electrospray mass spectra
were acquired at a solvent flow rate of 200 µL/min. Nitrogen was used for both the nebulizing and
drying gas. The data were obtained in a scan mode ranging from 100 to 1000 m/z or 250 to 1500 m/z to
in 0.7 s intervals.
Folded peptides were characterized using a Synapt G2-S high-definition MS system (Waters, Corp.,
Milford, MA, United States) equipped with an ESI source. Chromatographic separation was carried
out at a flow rate of 0.4 ml/min on a Acquity H-Class ultrahigh performance liquid chromatography
(UPLC) system (Waters, Corp., Milford, MA, United States), equipped with a Kinetex C18 100Å column
(100 mm × 2.1 mm, 2.6 mm particle size) from Phenomenex (LE PECQ France). The mobile phase
consisted of water (solvent A) and ACN (solvent B) with both phases acidified by 0.1% (v/v) formic
acid. Mass spectra were acquired over the range 50 Da to 1800 Da m/z every 0.1 second in the positive
ionization mode.
4.4. Preparative RP-HPLC
Preparative RP-HPLC was run on a Gilson PLC 2250 Purification system (Villiers le Bel, France)
instrument using a preparative column (Waters DeltaPak C18 Radial-Pak Cartridge, 100 Å, 40 × 100 mm,
15 µm particle size, flow rate 50.0 mL/min). Buffer A was 0.1% TFA in water, and buffer B was 0.1%
TFA in acetonitrile.
4.5. NMR Spectroscopy
Lyophilized synthetic peptides (~1-1.5 mg) were resuspended in 90% H2O:10% D2O. 2D 1H-1H
TOCSY, 1H-1H NOESY, 1H-1H DQF-COSY, 1H-15N HSQC, and 1H-13C HSQC spectra were acquired
at 290 K using a 600 MHz AVANCE III NMR spectrometer (Bruker, Karlsruhe, Germany) equipped
with a cryogenically cooled probe. D2O (99.9%) was obtained from Cambridge Isotope Laboratories,
Woburn, MA for 1H NMR measurements. All spectra were recorded with an interscan delay of 1 s.
NOESY spectra were acquired with mixing times of 200-250 ms, and TOCSY spectra were acquired
with isotropic mixing periods of 80 ms. Spectra were referenced to the water signal. Two-dimensional
spectra were collected over 4096 data points in the f2 dimension and 512 increments in the f1 dimension
over a spectral width of 12 ppm. Standard Bruker pulse sequences were used with an excitation
sculpting scheme for solvent suppression. Slow exchange experiments were performed by dissolving
lyophilized peptide in D2O and recording sequential rounds of 1D and 1H-1H TOCSY spectra and
monitoring the amide proton exchange. Spectra were processed using TOPSPIN (Bruker, Karlsruhe,
Germany) and analyzed using CCPNMR. The assignments were made using established protocols [27]
and the secondary shifts derived by subtracting the random coil αH shift [28] from the experimental αH
shifts. The two-dimensional NOESY spectra of the conopressin peptides were automatically assigned
and an ensemble of structures calculated using the program CYANA [29]. Torsion-angle restraints
from DANGLE [30] were used in the structure calculations. The final structures were visualized using
Pymol (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.) and MOLMOL [31].
4.6. Cell Culture Method and Transient Expression of Human and Zebrafish Oxytocin and Arginine
Vasopressin Receptors
The human oxytocin receptor (hOTR), the human arginine vasopressin receptor V1a (hV1aR),
the human arginine vasopressin receptor V1b (hV1bR) and the human arginine vasopressin receptor V2
(hV2R) complementary DNAs (cDNAs) were obtained from OriGene Technologies. The corresponding
Mar. Drugs 2020, 18, 150 12 of 14
arginine vasopressin zebrafish (ZF) receptors; arginine vasopressin receptor 1Ab (V1a1, The National
Center for Biotechnology Information (NCBI) accession number NP_001284605.1), arginine vasopressin
receptor 1Aa (V1a2, NCBI accession number NP_001288043.1), arginine vasopressin receptor 2 (V2,
NCBI accession number NP_001103595.1) and the oxytocin receptor (OTR, NCBI accession number
NP_001186299.1), were synthetically synthesized by GenScript.
COS-1 cells (American Type Culture Collection (ATCC)) grown in Dulbecco’s modified Eagle’s
medium (DMEM) and 5% fetal bovine serum (FBS) were transiently transfected with plasmid DNA
encoding the hOTR, hV1aR, hV1bR, hV2, ZF V1a1, ZF V1a2, ZF V2 and ZF OTR using FuGENE HD in
a 1:3 ratio of DNA and FuGENE, following the manufacturer’s protocol.
4.7. FLIPR Assay Measuring Intracellular Ca2+ Responses
At 24 h post-transfection, transiently transfected COS-1 cells were seeded at a density of
15,000 cells/well in 384-well black-walled imaging plates (Corning, Sigma-Aldrich) and maintained
for another 24 h at 37◦C in a 5% humidified CO2 incubator. The assay measuring the ligand-induced
Ca2+ responses was performed 48 h post-transfection. On the day of the assay, cells were loaded with
the Calcium 4 No-wash dye (Molecular Devices) by diluting the lyophilized dye in a physiological salt
solution (PSS: 140 mM NaCl, 11.5 mM glucose, 5.9 mM KCl, 1.4 mM MgCl2, 1.2 mM NaH2PO4, 5 mM
NaHCO3, 1.8 mM CaCl2, 10 mM HEPES, pH 7.4), and incubated for 30 min at 37◦C in a 5% humidified
CO2 incubator. Intracellular Ca2+ responses were measured in response to ligands in a Fluorometric
Imaging Plate Reader (FLIPR) (Molecular Devices) using a cooled CCD camera with excitation at
470–495 nm and emission at 515–575 nm. Camera gain and intensity were adjusted for each plate to
yield a minimum of 1000 arbitrary fluorescence units (AFU) baseline fluorescence. Prior to addition of
control agonists or conopressins, 10 baseline fluorescence readings were taken, followed by fluorescent
readings every second for 300 s. Concentration-response curves were established by plotting Delta F/F0
values, where F0 is the base-line level of fluorescence and Delta F is the change in fluorescence from
the baseline level, against agonist concentration using Prism (GraphPad Software). The conopressins
were also tested for antagonist activity at the human and ZF receptors. After the addition of 10 µM
conopressin peptide, cells were incubated for 10 minutes before stimulating the receptors with an EC90
concentration of agonists (oxytocin for the hOTR (0.5 µM), vasopressin for hV1a and hV1b (1 µM),
vasotocin for ZF V1a1, V1a2, V2 and OTR (0.1 µM)). Changes in fluorescence responses were assessed
for 10 s to set the baseline, then 600 s after addition of antagonist and for a further 300 s after addition
of agonists, using the FLIPR as previously described.
4.8. LANCE Ultra cAMP Assays
Assays measuring cAMP accumulation were performed 48 hours after transfection following
the manufacturer’s instructions (LANCE Ultra cAMP kit, PerkinElmer, Melbourne, Victoria, Australia).
To test for agonist activity at the hV2R, increasing concentrations of control agonists or conopressins
(10 pM to 100 µM) were added to 500 transfected cells in stimulation buffer in a white 384-well
plate (OptiPlate, PerkinElmer Life Sciences). When testing the conopressins for antagonist activity,
conopressins (100 µM) were added in the presence of an EC90 concentration of vasopressin (0.1 nM
agonist) to the cells as previously described. The plates were incubated for 30 min at room
temperature. Cells were then lysed by the addition of the europium (Eu) chelate-labeled cAMP
tracer and the cAMP-specific monoclonal antibodies labeled with the ULight dye, diluted in cAMP
detection buffer (LANCE Ultra cAMP kit, PerkinElmer), followed by incubation for 1 hour at room
temperature. The emission signals were measured at 615 and 665 nm after excitation at 340 nm using
a Tecan microplate reader (Tecan, Melbourne, Victoria, Australia).
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4.9. Analysis of the mRNA Pool isolated from Conus miliaris Venom Gland
RNA extraction, cDNA Library, 454 sequencing and assembly has been performed has described
by Dutertre et al. [32]. A comprehensive analysis of C. miliaris venom transcriptome will be
published elsewhere.
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